Transaction DateRecipientSharesTypePriceValue
30th December 2020Capital, Llc Ikarian520,291Open or private purchase$9.61$4,999,996.51
29th December 2020Charles Theuer1,000Open or private purchase$9.98$9,980.00
29th December 2020Mark C Wiggins997Open or private purchase$10.57$10,538.29
29th December 2020Mark C Wiggins3Open or private purchase$10.56$31.68
22nd December 2020Management Inc. Opaleye657Open or private purchase$5.19$3,412.98
22nd December 2020Management Inc. Opaleye15,900Open or private purchase$5.19$82,597.32
22nd December 2020Management Inc. Opaleye496,277Open or private purchase$8.06$3,999,992.62
21st December 2020Management Inc. Opaleye2,059Open or private purchase$5.24$10,787.92
21st December 2020Management Inc. Opaleye51,400Open or private purchase$5.24$269,305.16
18th December 2020Management Inc. Opaleye1,400Open or private purchase$5.31$7,437.64
Tracon Pharmaceuticals
Tracon Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

TRACON Pharmaceuticals, Inc. engages in the development and commercialization of targeted therapies for cancer, ophthalmic, and fibrotic diseases. Its products include TRC105, an anti-endoglin antibody for the treatment of solid tumor types. The company was founded in 2004 and is headquartered in San Diego, CA.

Ticker: TCON
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1394319
Employees: 19
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.
Red Flags
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
Fundamentals
Red Flag analysis based on Klaus Henselmann / Elisabeth Scherr paper
News
Generic placeholder
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China for Priority Review

19th January 2021

Generic placeholder
TRACON Pharmaceuticals to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

6th January 2021

Generic placeholder
TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines

30th December 2020

Generic placeholder
TRACON Pharmaceuticals Announces $5.0 Million Registered Direct Offering

29th December 2020

Generic placeholder
TRACON Pharmaceuticals Announces $8.8 Million Registered Direct Offering

22nd December 2020

Generic placeholder
TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial

10th December 2020